Nicholas School of the Environment, Duke University, Durham, NC, USA.
School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.
Lancet Diabetes Endocrinol. 2020 Aug;8(8):719-730. doi: 10.1016/S2213-8587(20)30128-5.
Endocrine-disrupting chemicals (EDCs) substantially cost society as a result of increases in disease and disability but-unlike other toxicant classes such as carcinogens-have yet to be codified into regulations as a hazard category. This Series paper examines economic, regulatory, and policy approaches to limit human EDC exposures and describes potential improvements. In the EU, general principles for EDCs call for minimisation of human exposure, identification as substances of very high concern, and ban on use in pesticides. In the USA, screening and testing programmes are focused on oestrogenic EDCs exclusively, and regulation is strictly risk-based. Minimisation of human exposure is unlikely without a clear overarching definition for EDCs and relevant pre-marketing test requirements. We call for a multifaceted international programme (eg, modelled on the International Agency for Research in Cancer) to address the effects of EDCs on human health-an approach that would proactively identify hazards for subsequent regulation.
内分泌干扰化学物质（EDCs）会导致疾病和残疾的增加，从而给社会带来巨大的成本，但与其他有毒物质类别（如致癌物质）不同，它们尚未被归类为危害类别并纳入法规。本系列论文探讨了限制人类 EDC 暴露的经济、监管和政策方法，并描述了潜在的改进措施。在欧盟，EDCs 的一般原则要求将人类暴露最小化、将其确认为高度关注物质，并禁止在农药中使用。在美国，筛选和测试计划仅针对雌激素 EDC 进行，监管完全基于风险。如果没有明确的 EDC 总体定义和相关的上市前测试要求，人类暴露的最小化是不可能的。我们呼吁开展一个多方面的国际计划（例如，仿照国际癌症研究机构），以解决 EDC 对人类健康的影响，这种方法将主动识别危害，以便随后进行监管。
